Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II StudyNaval Daver, Hagop M. Kantarjian, Guillermo Garcia‐Manero et al.|Cancer Discovery|2018Cited by 570
Ibrutinib and Venetoclax for First-Line Treatment of CLLNitin Jain, William G. Wierda, Maro Ohanian et al.|New England Journal of Medicine|2019Cited by 502
Clinical experience with the <scp>BCL</scp>2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignanciesCourtney D. DiNardo, Marina Konopleva, Caitlin R. Rausch et al.|American Journal of Hematology|2017Cited by 437
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemiaHagop Kantarjian, Emil J. Freireich, Farhad Ravandi et al.|Blood|2010Cited by 399
Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtypeNitin Jain, Joseph D. Khoury, Audrey L. Lamb et al.|Blood|2016Cited by 346